December 2012. Volume 8. Number 4

The new multicomponent meningococcal serogroup B vaccine has proven a good short term immunogenicity

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379:617-24
Reviewers: Llerena Santa Cruz E1, Buñuel Álvarez JC2.
1Hospital Universitario Dr. Josep Trueta. Girona. Girona. España.
2Àrea Bàsica de Salut Girona-4. Institut Català de la Salut. Girona. España.
Correspondence: Enrique Llerena Santa Cruz. Email: santum7@yahoo.com
Reception date: 01/11/2012
Acceptance date: 02/11/2012
Publication date: 28/11/2012

Abstract

Authors´conclusions: on the basis of immunogenicity responses this study provides evidence for an adolescent  aga 4CMenB vaccine schedule of two doses, 1-6 months apart, to provide portection against meningococcal B infection. The extent of this protection against meningococcus B variants circulating worldwide will be determined by national surveys.

Reviewers´commentary: the results of this study support the utility of this new vaccine as local reactogenictity until one month  . Recommendations and implementation strategies will depend on knowledge of the predominant strains.

How to cite this article

Llerena Santa Cruz E, Buñuel Álvarez JC. La nueva vacuna multicomponente para el meningococo serogrupo B en adolescentes tiene una buena inmunogenicidad a corto plazo. Evid Pediatr. 2012:8;73.

AVC | Critically appraised articles

Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, et al; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379:617-24
Reviewers: Llerena Santa Cruz E1, Buñuel Álvarez JC2.
1Hospital Universitario Dr. Josep Trueta. Girona. Girona. España.
2Àrea Bàsica de Salut Girona-4. Institut Català de la Salut. Girona. España.
Correspondence: Enrique Llerena Santa Cruz. Email: santum7@yahoo.com
Reception date: 01/11/2012
Acceptance date: 02/11/2012
Publication date: 28/11/2012

How to cite this article

Llerena Santa Cruz E, Buñuel Álvarez JC. La nueva vacuna multicomponente para el meningococo serogrupo B en adolescentes tiene una buena inmunogenicidad a corto plazo. Evid Pediatr. 2012:8;73.

References

  1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27:B51-63.
  2. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;3:483-6.
  3. Juanes de Toledo B, Ruiz Canela J. Un paso más para la vacuna frente al meningococo B dentro del calendario vacunal. Evid Pediatr. 2012;8:37.
  4. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573-82.
  5. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. PNAS. 2010;107:19490-5.
28/11/2012

Linked Comment